Federal contract award
75F40122C00203
GENE-RADAR? MOBILE DEVICE & NANOBIOSYM DIGITAL DX PLATFORM FOR PRECISION MOBILE DIAGNOSIS - BAA-EETWP # 66.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541713 — Research and Development in Nanotechnology |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $14.6M |
| Current contract value | $14.6M |
| Potential contract value / ceiling | $55.3M |
| Start date | Sep 27, 2022 |
| Current end date | Apr 28, 2025 |
| Potential end date | Sep 28, 2025 |
| Latest award activity | May 5, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 5, 2025 | P00003 | $0 | THE PURPOSE OF THIS ADMINISTRATIVE MODIFICATION IS TO CHANGE THE COR TO HOWARD S. YABLON. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 20, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 20, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.